Trade Organovo Holdings, Inc. - ONVO CFD

Trading Conditions

• Spread: 0.05
• Long position overnight feeLong position overnight feeMargin. Your investmentUS$1,000.00Overnight feeCharges from full value of position-0.026179 %(-US$1.05)Trade size with leverage ~ US$5,000.00Short position overnight fee ~ US$4,000.00Go to platform: -0.026179%
• Short position overnight feeShort position overnight feeMargin. Your investmentUS$1,000.00Overnight feeCharges from full value of position0.003957 %(US$0.16)Trade size with leverage ~ US$5,000.00Short position overnight fee ~ US$4,000.00Go to platform: 0.003957%
• Overnight fee time: 21:00 (UTC)
• Currency: USD
• Min traded quantity: 1
• Margin: 20
• Stock exchange: United States of America
• Commission on trade: 0%

• Margin. Your investment: US$1,000.00
• Overnight feeCharges from full value of position: -0.026179 %
  (-US$1.05)

• Margin. Your investment: US$1,000.00
• Overnight feeCharges from full value of position: 0.003957 %
  (US$0.16)

Key Stats

• Prev. Close: 0.97
• Open: 0.96
• 1-Year Change: -45.76%
• Day's Range: 0.96 - 0.98

Organovo Holdings, Inc. Company profile

About Organovo Holdings Inc

Organovo Holdings, Inc. is an early stage biotechnology company. The Company is focused on building high fidelity, three-dimensional (3D) tissues that recapitulate key aspects of human disease. The Company is targeting the intestine and has ongoing 3D tissue developments in Ulcerative colitis (UC) and Crohn's disease (CD). The Company uses its platform technology to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function and disease. Its NovoGen Bioprinters are automated devices that enable the fabrication of 3D living tissues comprised of mammalian cells. NovoGen Bioprinters can dispense pure hydrogel formulations and also serve as important components of company's tissue prototyping and manufacturing platform. The Company also intends to use its bioprinting platform as well as 3D technologies to treat its target diseases.

Financial summary

BRIEF: For the nine months ended 31 December 2021, Organovo Holdings Inc revenues was not reported. Net loss decreased 33% to $9.5M. Lower net loss reflects Non-cash stock-based compensation decrease of 78% to $1.2M (expense), Gain (loss) on fixed asset disposals decrease from $19K (expense) to $0K, Other income increase from $6K to $25K (income). Basic Earnings per Share excluding Extraordinary Items increased from -$2.15 to -$1.10.

Equity composition

Common Stock $.0001 Par, 06/12 Shares auth.75M and o/s 43,772,483. Insiders 39.83%. 02/12, 10.59135-for-1 Stock split.